Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Oncogene ; 38(15): 2750-2766, 2019 04.
Article in English | MEDLINE | ID: mdl-30542118

ABSTRACT

Poly(ADP-ribosyl)ation (PARylation) is a post-translational modification by which poly ADP-ribose (PAR) polymers are covalently added to proteins through a PAR polymerase (PARP). Here, using proteomic approach, we identify the transcriptional regulator, OVOL2, is a novel substrate of PARP1 and can be PARylated at residues Lysine 145, Lysine 176, and Lysine 212 within its C2H2 zinc finger domains. Overexpression of PARylated OVOL2 alters cell morphology and induces lagging chromosomes and aneuploidy. To define the underlying molecular mechanism by which OVOL2 induces abnormal cell cycle and centrosome amplification, we uncover that the OVOL2 elevates the protein levels of Cyclin E by enhancing its stability. Furthermore, we identify Skp2, the E3 ubiquitin ligase of Cyclin E, as a direct target of PARylated OVOL2. Using ChIP assay, the OVOL2 binding site on the promoter region of Skp2 is mapped. To further explore the physiological effect, we show that PARylated OVOL2 can induce cell death. Furthermore, to investigate PARylated OVOL2 function in vivo, we further develop a null-mice xenograft model and generate MMTV-PyVT transgenic mice and monitor the effect of wild-type OVOL2 and non-PARylated OVOL2-3K/A mutants on tumor progression. Consistently, overexpression of wild-type OVOL2 in both null-mice xenograft and MMTV-PyVT transgenic mice displays significantly reduction of tumor progression, respectively, further indicating that the function of OVOL2 as a tumor suppressor in vivo is highly regulated by PARylation. Taken together, our study sheds new light on PARP1-induced PARylation as a critical event in the OVOL2-mediated regulation of chromosomal integrity and suppression of cancer cells growth.


Subject(s)
Cell Death/genetics , Poly ADP Ribosylation/genetics , Poly Adenosine Diphosphate Ribose/genetics , Transcription Factors/genetics , Aneuploidy , Animals , Binding Sites/genetics , Cell Cycle/genetics , Cell Line, Tumor , Cell Proliferation/genetics , Centrosome/physiology , Chromosomes/genetics , Cyclin E/genetics , Female , Heterografts , Humans , Mice , Mice, Transgenic , Poly (ADP-Ribose) Polymerase-1/genetics , Promoter Regions, Genetic/genetics , Proteomics/methods , S-Phase Kinase-Associated Proteins/genetics , Transcription, Genetic/genetics , Ubiquitin-Protein Ligases/genetics
2.
J Pharm Biomed Anal ; 162: 9-15, 2019 Jan 05.
Article in English | MEDLINE | ID: mdl-30219599

ABSTRACT

N6-methyladenosine (m6A) is the most prevalent internal modification of eukaryotic messenger RNA (mRNA). Until now, two RNA demethylases have been identified, including FTO (fat mass and obesity-associated protein) and ALKBH5 (α-ketoglutarate-dependent dioxygenase alkB homologue 5). As a mammalian m6A demethylase, ALKBH5 significantly affects mRNA export and RNA metabolism as well as the assembly of mRNA processing factors in nuclear speckles, and ALKBH5 may play a significant role in these biological processes. Nevertheless, no modulator of ALKBH5 has been reported. The reason for that may be the lack of in vitro assays for ALKBH5 inhibitor screening. Herein, we describe the development of two homogeneous assays for ALKBH5 using N6-methyladenosine as substrate with different principles. Using ALKBH5 recombinant, we developed a formaldehyde dehydrogenase coupled fluorescence based assay and an antibody based assay for the activity evaluation of ALKBH5. These robust coupled assays are suitable for screening ALKBH5 inhibitors in 384-well format (Z' factors of 0.74), facilitating the discovery of modulators in the quest for the regulation of biological processes.


Subject(s)
Adenosine/analogs & derivatives , Aldehyde Oxidoreductases/metabolism , AlkB Homolog 5, RNA Demethylase/metabolism , Drug Discovery/methods , Fluorescent Antibody Technique , Formaldehyde/metabolism , High-Throughput Screening Assays/methods , RNA, Messenger/metabolism , Adenosine/metabolism , Aldehyde Oxidoreductases/antagonists & inhibitors , AlkB Homolog 5, RNA Demethylase/antagonists & inhibitors , Demethylation , Enzyme Inhibitors/pharmacology , Humans , Kinetics , Reproducibility of Results , Spectrometry, Fluorescence
3.
Diabetes ; 67(12): 2569-2584, 2018 12.
Article in English | MEDLINE | ID: mdl-30279163

ABSTRACT

Wnt/ß-catenin signaling plays a key role in regulating adipogenesis through indirectly inhibiting the expression of C/EBPα and peroxisome proliferator-activated receptor γ (PPARγ); however, the detailed molecular mechanism remains poorly understood. Moreover, the factor(s) that determines the Wnt/ß-catenin output level during adipogenesis is also not completely defined. In this study, we showed that Pygo2 exhibited a declined expression pattern during adipocyte differentiation, resulting in an attenuated Wnt/ß-catenin output level. The mechanism study indicated that Pygo2 inhibition led to the downregulation of Axin2, a constitutive Wnt target, in the cytoplasm. Consequently, Axin2-bound GSK3ß was released and translocated into the nucleus to phosphorylate C/EBPß and Snail, resulting in an increase in the DNA binding activity of C/EBPß and decreased protein stability of Snail, which subsequently activated the expression of C/EBPα and PPARγ. Consistent with this, embryonic fibroblasts from Pygo2-/- mice exhibited spontaneous adipocyte differentiation, and adipocyte precursor-specific Pygo2-deficient mice exhibited increased adiposity with decreased energy expenditure. We further showed impaired glucose tolerance and decreased systemic insulin sensitivity in Pygo2-deficient mice. Our study revealed an association between Pygo2 function and obesity or diabetes.


Subject(s)
Adiposity/genetics , Blood Glucose/metabolism , Homeostasis/genetics , Intracellular Signaling Peptides and Proteins/metabolism , Wnt Signaling Pathway/physiology , Adipocytes/metabolism , Adipogenesis/genetics , Adipose Tissue, White/metabolism , Animals , Axin Protein/metabolism , Body Composition/genetics , Glycogen Synthase Kinase 3 beta/metabolism , Intracellular Signaling Peptides and Proteins/genetics , Mice , Mice, Knockout , beta Catenin/metabolism
4.
Oncotarget ; 8(24): 39401-39416, 2017 Jun 13.
Article in English | MEDLINE | ID: mdl-28455959

ABSTRACT

Great progress has been achieved in the study of the role of TGF-ß signaling in triggering epithelial-mesenchymal transition (EMT) in a variety of cancers; however, the regulation of TGF-ß signaling during EMT in mammary tumor metastasis has not been completely defined. In the present study, we demonstrated that OVOL2, a zinc finger transcription factor, inhibits TGF-ß signaling-induced EMT in mouse and human mammary tumor cells, as well as in mouse tumor models. Data from the Oncomine databases indicated a strong negative relationship between OVOL2 expression and breast cancer progression. Moreover, our experiments revealed that OVOL2 inhibits TGF-ß signaling at multiple levels, including inhibiting Smad4 mRNA expression and inducing Smad7 mRNA expression, blocking the binding between Smad4 and target DNA, and interfering with complex formation between Smad4 and Smad2/3. These findings reveal a novel mechanism that controls the TGF-ß signaling output level in vitro and in vivo. The modulation of these molecular processes may represent a strategy for inhibiting breast cancer invasion by restoring OVOL2 expression.


Subject(s)
Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Epithelial-Mesenchymal Transition , Signal Transduction , Transcription Factors/metabolism , Transforming Growth Factor beta/metabolism , Animals , Biomarkers , Breast Neoplasms/genetics , Breast Neoplasms/mortality , Cell Line, Tumor , Cell Movement , Cell Proliferation , DNA-Binding Proteins/metabolism , Disease Models, Animal , Epithelial-Mesenchymal Transition/genetics , Female , Humans , Kaplan-Meier Estimate , Mice , Neoplasm Metastasis , Prognosis , Protein Binding , Smad4 Protein/genetics , Smad4 Protein/metabolism , Smad7 Protein/genetics , Smad7 Protein/metabolism , Transcription Factors/genetics , Tumor Suppressor Proteins/genetics , Tumor Suppressor Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL